Lupin Ltd partner Sandoz launches biosimilar ranibizumab Ranluspec across Europe, excluding Germany
- Launch follows European Commission approval of vial and pre-filled syringe presentations.
- Ranluspec is indicated for several retinal and choroidal vascular conditions.
